Human Health Portfolio ARMGO Pharma Publishes Positive Phase 1b Trial Results of Rycal® ARM210 for the Treatment of Ryanodine Receptor 1 Related Myopathies gennaio 29, 2024 PDF 108,4 KB Download
Human Health Portfolio ARMGO Pharma Enrolls First Patient in Phase 2 Trial of ARM210 for the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia luglio 19, 2023 PDF 82,8 KB Download
Human Health Portfolio Forbion leads $35M Series B for ARMGO Pharma dicembre 20, 2021 PDF 104,3 KB Download